Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points

MeSH terms

• Bisphosphonate-Associated Osteonecrosis of the Jaw* / etiology
• Bisphosphonate-Associated Osteonecrosis of the Jaw* / pathology
• Bone Density Conservation Agents* / adverse effects
• Bone Neoplasms* / drug therapy
• Bone Neoplasms* / secondary
• Denosumab / adverse effects
• Diphosphonates / adverse effects
• Humans
• Osteonecrosis* / chemically induced